Baycol (cerivastatin sodium)


Approval Status
Approved June 1997; withdrawn 8/8/01

Treatment for

Cardiovascular / Cardiology , Diabetes / Endocrinology

Baycol (cerivastatin sodium), a new cholesterol-lowering agent by Bayer Corporation, was initially FDA approved in 1997. Baycol is a statin indicated as an adjunct to diet for patients with primary hypercholesterolemia and mixed dyslipidemia who have not responded adequately to dietary restrictions and other non-pharmacological measures. Baycol has been shown to be effective at relatively low doses at lowering LDL-cholesterol as well as total cholesterol and triglycerides.

However, the company voluntarily withdrew Baycol from the market on August 8, 2001 because of reports of sometimes fatal rhabdomyolysis, a severe muscle adverse reaction from the cholesterol-lowering product. The FDA received reports of 31 US deaths due to severe rhabdomyolsis from Baycol.

Baycol (cerivastatin sodium) Drug Information

The Baycol (cerivastatin sodium) drug information shown above is licensed from Thomson CenterWatch. The information provided here is for general educational purposes only and does not constitute medical or pharmaceutical advice which should be sought from qualified medical and pharmaceutical advisers.

Scroll to top